European Respiratory Journal

Article	Citations
The right ventricle tamed	1059
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis	793
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?	667
Chymase-1: a “MAST”-er switch in COPD?	344
The Cochrane review of electronic cigarettes for smoking cessation: remaining focused on the evidence	234
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease	212
Missing airways, ventilation defects and conductive airway physiology in asthma	201
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe	175
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow	164
A breath of the future: a novel human model for COPD and beyond	147
Randomised controlled trials utilisingFENOto manage asthma: is it time to acknowledge that “one size does not fit all”?	145
The lung that rules the heart	145
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?	133
Antiviral CD8+T-cell immune responses are impaired by cigarette smoke and in COPD	131
A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis	128
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan	125
The NIVO score: can it help to improve noninvasive ventilation in daily clinical practice?	123
“The Noninvasive Ventilation Outcomes (NIVO) score: prediction of in-hospital mortality in exacerbations of COPD requiring assisted ventilation.” Tom Hartley, Nicholas D. Lane, John Steer,et al	121
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)	115
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet	115
Combining rituximab with mycophenolate for the treatment of interstitial lung disease	109
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD	107
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study	97
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial	97
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection	96

RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD	93
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections	93
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey	90
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea	88
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis	84
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	84
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis	83
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target	82
Treatment algorithm for pulmonary arterial hypertension	82
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?	81
The environmental impact of inhaled therapy: making informed treatment choices	81
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study	81
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor	81
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis	80
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era	78
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation	78
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume	78
The association between immunosuppressants and outcomes of COVID-19	77
Genomic classifier for usual interstitial pneumonia combined with bronchoalveolar lavage cellular profile: potential use in the clinical management of new onset ILD?	77
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?	76
Small packages but big insights: extracellular vesicles as biomarkers in interstitial lung disease associated with systemic sclerosis	76
Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis	75
Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study	74
Chronic lung allograft dysfunction phenotype and prognosis by machine learning CT analysis	74
Vitamin D deficiency, a potential cause for insufficient response to sildenafil in pulmonary arterial hypertension	74
The limits of normal of pulmonary arterial wedge pressure	73
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough	72
Reply: Tuberculosis screening in migrants to the EU/EEA and UK	72
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?	72
Clean air for healthy lungs – an urgent call to action: European Respiratory Society position on the launch of the WHO 2021 Air Quality Guidelines	71
Screening asymptomaticBMPR2mutation carriers: a new frontier for pulmonary hypertension physicians?	69
Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis	66
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?	63
Pleural mesothelioma: surgery questioned again?	63
List ofEuropean Respiratory Journalpeer reviewers 2023	61
The efficacy of singingversusexercise training: do the data really support the authors’ conclusions?	60
FEV1Q: what (even) is normal lung function?	59
“Age-related changes in plasma biomarkers and their association with mortality in COVID-19.” E.H.A. Michels, B. Appelman, J. de Brabander,et al.Eur Respir J2023; 62: 2300011.	59
Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain	58
Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination	57
The association of eicosanoids and eicosanoid-related metabolites with pulmonary hypertension	57
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19	56
CPAP recall and cancer risk: should we be concerned?	56
Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study	55
Real-world monitoring of elexacaftor/tezacaftor/ivacaftor trough concentrations in adults with cystic fibrosis	55
WHO online guide on the use of digital technologies for tuberculosis programmes	55
Particulate matter–related ITIH4 deficiency is associated with an emphysema phenotype of chronic obstructive pulmonary disease through JNK-dependent and JNK-independent signaling	55
Prognostic phenotypes of early-stage lung adenocarcinoma	54
Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study	54
Single-inhaler tripleversusdual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety	53

Profiling of lung SARS-CoV-2 and influenza virus infection dissects virus-specific host responses and gene signatures	53
Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis	53
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension	52
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme	50
Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients	50
Childhood asthma: pathogenesis and phenotypes	49
Theratyping in cystic fibrosis: filling the knowledge gaps	48
Reply: The new ERS/ATS standards on lung function test interpretation: some extant limitations	48
Transcriptomic clustering of critically ill COVID-19 patients	48
Early-life exposure to mixture of phenols and respiratory health in pre-school children	47
Risk assessment of systemic sclerosis-associated pulmonary arterial hypertension: cardiac indexversusstroke volume index	47
Right ventricular–pulmonary arterial coupling and its relationship to exercise haemodynamics in a continuum of patients with pulmonary vascular disease due to chronic thromboembolism	47
Is tezepelumab more than just an anti-eosinophil drug?	46
The dawn of the omics era in human precision-cut lung slices	46
Metabolomics in pulmonary medicine: extracting the most from your data	46
Pulmonary arterial hypertension and CFTR: the paradox of going forward by tacking sideways!	45
Comment on: Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis	45
Muscle sympathetic nerve activity and adaptive servo-ventilation: questions remain	45
Vocal cord paralysis as a rare complication of bronchoscopic lung volume reduction: a case series of five patients	45
Oral corticosteroids in asthma and beyond: moving forward	44
Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease	44
Unravelling the unmet needs of patients with severe dyspnoea: a case for palliative oxygen	43
Reply to: Cause or consequence?	43
“Bronchial thermoplasty decreases airway remodelling by blocking epithelium-derived heat shock protein-60 secretion and protein arginine methyltransferase-1 in fibroblasts.” Qingzhu Sun, Lei Fang, Mic	43
Oxygen therapy target ranges: finding the balance	43
An attack of asthma is not an attack of the heart: clarifying causal links between asthma and incident coronary heart disease	42
ERJPodcast October 2023: ERS short guidelines for the use of as-needed ICS/formoterol in mild asthma	41
Cardiopulmonary response to exercise in adults born very preterm	41
MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study	41
Contributions to simplifying the global interpretation of spirometry: high quality spirometry data from Asia	41
Less is more? Antibiotic treatment duration for exacerbations of bronchiectasis	41
Liver cancer in severe alpha-1 antitrypsin deficiency: who is at risk?	41
Evaluation of the PADIS score stratifying risk for venous thromboembolism recurrence after a first unprovoked pulmonary embolism: results from the REVERSE study	41
Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney/liver disease	40
Bronchoconstriction with inhaled ATP in healthy volunteers	40
Multitasking within the airway epithelium	40
COVID-19 changed the world – without changing CTEPH	40
ERJPodcast January 2024: The microbiome in early life and childhood asthma	40
Unbowed, unbent, unbroken: predicting pulmonary hypertension using echocardiography	40
Heart rate response and cardiovascular risk during obstructive sleep apnoea: an easy biomarker derived from pulse oximetry	39
Tailored approaches facilitate high completion of tuberculosis infection treatment among migrants	39
Prolonged higher dose methylprednisoloneversusconventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)	38
Indoor microbiome, microbial and plant metabolites, chemical compounds, and asthma symptoms in junior high school students: a multicentre association study in Malaysia	38
Epigenetic age among US adults with chronic respiratory diseases: results from NHANES 1999–2002	38
Skewed adaptive immune responses are involved in alpha-1 antitrypsin deficiency emphysema	38
European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases	37
Respective roles of non-pharmaceutical interventions in bronchiolitis outbreaks: an interrupted time-series analysis based on a multinational surveillance system	37
Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity	37
European Respiratory Society guidelines for the diagnosis of asthma in adults	37
Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis	37
Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA	37
Air pollution and COPD: GOLD 2023 committee report	36
What can lockdowns tell us about the underlying causes of asthma exacerbations? A retrospective cohort study	36
Spirometry forced expiratory time is driven by airflow limitation in asthmatic children	36
Flavonoid intakes inversely associate with COPD in smokers	36
Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud	36
Presenting clinical data for the hazard classification of chemical respiratory sensitisers	36
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension	36
Moving the dial on identifying endotypes of asthma from early life	36
I love you with all my lungs: a viewpoint on communicating effectively and positively about lung health	36
Mechanical ventilation promotes lung tumour spread by modulation of cholesterol cell content	36
Evolving diagnostic techniques in mediastinal lymphadenopathy: is mediastinal cryobiopsy the new kid on the block?	35
Respiratory support and bronchopulmonary dysplasia in infants born at 22–26 weeks gestation in Sweden, 2004–2007 and 2014–2016	35
Aspergillussensitisation: an underappreciated treatable trait in airway disease	35
Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL−1	35
Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle	34
Lung function during and after acute respiratory infection in COVID-19 positive and negative outpatients	34
Tracing the origins of fibrotic fibroblasts: does the name matter? Look at the genes!	34
Technical standards for respiratory oscillometry and bronchodilator response cut-offs	34
Peripheral pulmonary artery stenosis in adults: a novel type of pulmonary vascular disease with a strong genetic background	33
Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: an F-MISO PET/CT study	33
Saliva molecular testing for SARS-CoV-2: simplifying the diagnosis without losing accuracy	32
ERJPodcast January 2025: Treatment response to mepolizumab in severe eosinophilic asthma	32
Health effects of exposure to residential air pollution in patients with pulmonary arterial hypertension: a cohort study in Belgium	32
Interalveolar pore morphology in (pre-)COPD stages and associations with small airways	32
The COVID-19 pandemic and pulmonary arterial hypertension in Italy: adaptation, outcomes and valuable lessons learned	32
Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: a self-controlled case series	32
Relieving dyspnoea through the brain	31
Lung structure and longitudinal change in cardiac structure and function: the MESA COPD Study	31
Dyspnoea in acutely ill mechanically ventilated adult patients: an ERS/ESICM statement	31

Ex vivodelivery of regulatory T-cells for control of alloimmune priming in the donor lung	31
Now we know: chronic exposure to air pollutants is a risk factor for the development of idiopathic pulmonary fibrosis	31
Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort	31
Combining digital adherence technology and therapeutic drug monitoring for personalised tuberculosis care	31
A range of 30–62% of functioning multiciliated airway cells is sufficient to maintain ciliary airway clearance	31
Asthma, COPD and their overlap: coexistence or something more?	31
Lung transplantation for acute respiratory distress syndrome: a retrospective European cohort study	31
Primary spontaneous pneumothorax: does size matter?	31
The role of precision medicine in interstitial lung disease	31
Incidence of interstitial lung abnormalities: the MESA Lung Study	30
Developing, validating, updating and judging the impact of prognostic models for respiratory diseases	30
Pathogenic variants inCFAP46,CFAP54,CFAP74andCFAP221cause primary ciliary dyskinesia with a defective C1d projection of the central apparatus	30
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or twoF508delalleles	30
Nasal airway microRNA profiling of infants with severe bronchiolitis and risk of childhood asthma: a multicentre prospective study	30
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studi	30
Pulmonary hypertension associated with left heart disease	30
The longitudinal microbial and metabolic landscape of infant cystic fibrosis: the gut–lung axis	30
Opioids for dyspnoea in interstitial lung disease: does the sequence and timing of therapy matter?	29
The identification of prevalent tuberculosis disease through infection screening among high-risk migrants in the Netherlands	29
NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance	29
ERJPodcast July 2023: The HISTORIC study	29
The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma	29
Antigen identification and avoidance on outcomes in fibrotic hypersensitivity pneumonitis	29
Extracorporeal life support as a bridge to lung transplantation strategy in anti-MDA5+ rapidly progressive interstitial lung disease is life-saving but with persistent difficulties at the bedside	29
Targeting AMPK and the Nrf2/HO-1 axis: a promising therapeutic strategy in acute lung injury	29
ERJPodcast December 2023: Year in review	29
List ofEuropean Respiratory Journalpeer reviewers 2022	29
“From pre-COPD to COPD: a Simple, Low cost and easy to IMplement (SLIM) risk calculator.” M.J. Divo, C. Liu, F. Polverino,et al.Eur Respir J2023; 62: 2300806.	29
Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse	29
All roads lead to COPD… or not?	28
Reply: Cognitive behavioural therapy sessions approach ineffective for anxiety and depression in COPD: is the door closed for good?	28
How bad is your cough? The McMaster Cough Severity Questionnaire as a new tool to measure chronic cough	28
Ensuring availability of respiratory medicines in times of European drug shortages	28
Dexamethasone for preterm infants at risk of bronchopulmonary dysplasia: is timing everything?	28
Protease activity sensors enable real-time treatment response monitoring in lymphangioleiomyomatosis	28
Predicting asthma exacerbations: is there utility in noninvasive assessment of distal airway inflammation using multiple flowFENO?	28
Up-regulated matrix metalloproteinase activity in soil-transmitted helminth–tuberculosis co-infection is associated with increased lung pathology	28
Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries	27
“Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.” Mark Toshner, Colin Church, Lars Harbaum,et al.Eur Respir	27
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial	27
Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study	27
Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis	27
Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma	27
Neutrophil elastase-dependent cleavage of LTA4H alters its aminopeptidase activity in cystic fibrosis	27
An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension	26
Low smoking exposure and development and prognosis of COPD over four decades: a population-based cohort study	26
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia	26
Extracorporeal photopheresis for the prevention of rejection after lung transplantation: a prospective randomised controlled trial	26
Integrating hot topics and implementation of treatable traits in asthma	26
Phenotyping the responses to systemic corticosteroids in the management of asthma attacks (PRISMA)	26
Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study	26
Sleep apnoea in the elderly: a great challenge for the future	26
Uptake and 4-week quit rates from an opt-out co-located smoking cessation service delivered alongside community-based low-dose computed tomography screening within the Yorkshire Lung Screening Trial	26
Genetic associations between Serotonin Receptor 1F (HTR1F) regulatory variation and sleep apnea in non-obese individuals: Insights from GWAS and eQTL analyses	26
Gut microbiota-derived succinate aggravates acute lung injury after intestinal ischaemia/reperfusion in mice	25
Management of pulmonary hypertension in special conditions	25
Association of blood trihalomethane concentrations with asthma in US adolescents: nationally representative cross-sectional study	25
Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis	25
A randomised trial of prednisoloneversusprednisolone and itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma	25
Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study	25
ERS statement on paediatric long-term noninvasive respiratory support	25
ERS technical standards for using type III devices (limited channel studies) in the diagnosis of sleep disordered breathing in adults and children	25
Tofacitinib in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a new standard of care emerges	25
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension	25
Pulse oximeter measurements vary across ethnic groups: an observational study in patients with COVID-19	25
Progressive pulmonary fibrosis: an expert group consensus statement	25
Reversible carfilzomib-induced pulmonary arterial hypertension: don't take your eyes off the ball!	24
Heart or lungs? Why not both!	24
Uncovering early COPD? The T-slope as a novel CT biomarker for evaluating airway narrowing	24
Drug-induced lung disease: unwanted collateral damage	24
The interface in home non-invasive ventilation: is the nasal mask better?	24
“Post tuberculosis”: the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials	24
Reply to: Insights on the ERS/ESTS statement on the management of pleural infection in adults	24
The rat takes the cheese: a novel model of CFTR-dependent chronic bacterial airway infection	24
AMR-Lung: a European Clinical Research Collaboration on antimicrobial resistance in chronic lung disease	23
TB or not TB: does AI have an answer for children?	23
Endothelial cells in pulmonary fibrosis: more than a bystander	23
Mycobacterium aviumcomplex genomics and transmission in a London hospital	23
“Interstitial lung abnormalities are associated with decreased mean telomere length.” R.K. Putman, G.T. Axelsson, S.Y. Ash,et al.Eur Respir J2022; 60: 2101814	23
Cancer risk associated with alpha-1-antitrypsin deficiency: only large registries will give us the answer	23
The ERS PROFILE.net Clinical Research Collaboration is dedicated to the set-up of an academic network to enhance imaging-based management of progressive pulmonary fibrosis	23
Deep phenotyping of unaffected carriers of pathogenicBMPR2variants screened for pulmonary arterial hypertension	23
The paradox of the safer cigarette: understanding the pulmonary effects of electronic cigarettes	23
Latent COPD: a proposed new term in the disease nomenclature	23
Comment on: Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case–control study in Sweden	23
Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9%versus3%versus6% nebulised saline	23
Impact of a rare respiratory diseases reference centre set-up on primary ciliary dyskinesia care pathway	23
Sequential multimodal therapy in chronic thromboembolic pulmonary hypertension with mixed anatomical lesions: a proof of concept	23
“Spatial transcriptomics for respiratory research and medicine.” S. Curras-Alonso, J. Soulier, T. Walter,et al.Eur Respir J2021; 58: 2004314	23
Tailored psychological intervention for anxiety or depression in COPD (TANDEM): a randomised controlled trial	22
How do people with COPD walk? A European study on digitally measured real-world gait	22
Right heart function during and after pregnancy in women with pulmonary arterial hypertension	22
The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor	22
Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis	22
The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?	22